Mouse Immune Cell Depletion Antibodies For In Vivo Use

Date: Mar 27, 2026

In immunology and the field of cell and gene therapy (CGT), selective elimination of defined cell populations—commonly referred to as cell depletion—is a widely adopted strategy to interrogate the functional roles of specific cellular subsets and their associated molecular targets.

InvivoCrown offers a range of monoclonal antibodies to mouse cell surface proteins for in vivo cell-specific depletion studies. These antibodies are validated for in vivo use, where systemic administration enables the targeted depletion of specific cell populations. Mechanistically, these depletion antibodies act through multiple effector pathways, including antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and antibody-dependent cellular phagocytosis (ADCP).

Our Most Popular Cell Depletion Antibodies:

Cell Type	Item Number	Name
T cells	IV0121	InVivoPro Anti-Mouse CD3ε in vivo antibody, Clone 145-2C11
CD4+T cells	IV0102	InVivoPro Anti-Mouse CD4 in vivo antibody, Clone GK1.5
CD8+T cells	IV0104	InVivoPro Anti-Mouse CD8α in vivo antibody, Clone 2.43
	IV0119	InVivoPro Anti-Mouse CD8α in vivo antibody, Clone 53-6.7
	IV0117	InVivoPro Anti-Mouse CD8β (Lyt 3.2) in vivo antibody, Clone 53-5.8
NKcells	IV0111	InVivoPro Anti-Mouse NK1.1(CD161) Antibody in vivo antibody, Clone PK136
Neutrophils	IV0113	InVivoPro Anti-Mouse Ly6G/Ly6C (Gr-1) in vivo antibody, Clone RB6-8C5
Neutrophils	IV0103	InVivoPro Anti-Mouse Ly6G in vivo antibody, Clone 1A8
Macrophages	IV0114	InVivoPro Anti-Mouse CSF1R (CD115) in vivo antibody, Clone AFS98
Monocytes	IV0113	InVivoPro Anti-Mouse Ly6G/Ly6C (Gr-1) in vivo antibody, Clone RB6-8C5
Monocytes	IV0114	InVivoPro Anti-Mouse CSF1R (CD115) in vivo antibody, Clone AFS98
B cells	IV0135	InVivoPro Anti-Mouse CD20 in vivo antibody, Clone MB20-11

Related News

: InvivoCrown-Flyer

: Functional Blocking Anti-C5 Antibody (Clone BB5.1): Dual Silencing of C5a and C5b Pathways ？
Complement component 5(C5) is a central hub of the complement cascade, with a molecular weight of approximately 190 kDa, composed of an α-chain (111 kDa) and a β-chain (75 kDa) linked by disulfide bonds. Upon cleavage by C5 convertase, C5 generates two potent effector molecules: C5a, a highly active anaphylatoxin and chemoattractant that drives the recruitment and activation of neutrophils and monocytes; and C5b, which initiates the formation of the membrane attack complex (MAC, C5b-9) leading to target cell lysis. Therefore, blocking C5 simultaneously inhibits terminal complement activation and downstream inflammatory signaling, while preserving upstream C3b-mediated opsonization—making C5

: Enhancing Tumor Immunotherapy: InVivoPro Anti-Mouse PD-1 (CD279) Antibody, Clone RMP1-14 for Preclinical Research
The InVivoPro Anti-Mouse PD-1 (CD279) in vivo antibody, Clone RMP1-14 has emerged as a pivotal tool in preclinical cancer immunotherapy research, enabling robust blockade of the PD-1/PD-L1 immune checkpoint pathway. This high-specificity monoclonal antibo